A retrospective case control analysis of the efficacy of Gardasil® vaccination in 28 patients with recurrent respiratory papillomatosis of the larynx

Abstract

Recurrent respiratory papillomatosis (RRP) of the larynx represents a significant disease burden to patients and the healthcare system

The use of HPV 6/11/16/18 vaccination (Gardasil^®) has previously been thought to impact on disease burden in patients with RRP.

Gardasil^® vaccination did not impact on the number of endolaryngeal surgical procedures required, the interval between procedures, or the number of patients who achieved disease remission in comparison to a control cohort.

This study indicates Gardasil^® vaccination does not appear to have any effect on disease burden in patients with RRP.

The use of a control cohort profiles the natural progression of RRP.

This article is protected by copyright. All rights reserved.